KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Gains from Investment Securities (2016 - 2025)

Novavax (NVAX) has 16 years of Gains from Investment Securities data on record, last reported at $229000.0 in Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 115.8% year-over-year to $229000.0; the TTM value through Sep 2025 reached -$5.9 million, down 172.4%, while the annual FY2023 figure was $7.0 million, 92.48% down from the prior year.
  • Gains from Investment Securities reached $229000.0 in Q3 2025 per NVAX's latest filing, up from -$6.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $67.7 million in Q3 2021 and bottomed at -$20.2 million in Q2 2022.
  • Average Gains from Investment Securities over 5 years is $14.1 million, with a median of $2.1 million recorded in 2024.
  • Peak YoY movement for Gains from Investment Securities: tumbled 777.58% in 2021, then surged 2211.27% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $64.0 million in 2021, then fell by 25.52% to $47.7 million in 2022, then crashed by 85.5% to $6.9 million in 2023, then tumbled by 120.96% to -$1.4 million in 2024, then skyrocketed by 115.8% to $229000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $229000.0 in Q3 2025, -$6.2 million in Q2 2025, and $1.5 million in Q1 2025.